ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Currently, patients in the EDELWEISS trial continue to receive linzagolix for an additional 12 weeks. Twenty-four-week data, including the bone mineral density (BMD) assessment, is expected to be available in the fourth quarter of 2018.  ObsEva subsequently intends to seek feedback from regulatory authorities on the design of a Phase 3 clinical trial program by the end of 2018.

Conference Call Information

ObsEva will host a conference call and audio webcast today at 8 a.m. Eastern Time/2 p.m. Central European Time, to discuss EDELWEISS top-line results and review the company`s strategic development plans. To participate in the conference call, please dial +1(844) 419-1772 for U.S. callers and +1(213) 660-0921 for international callers, and refer to conference ID 9839439. The webcast can be accessed under the "Investors" section of ObsEva`s website www.obseva.com.

About Endometriosis

Endometriosis is associated with a multitude of symptoms, most common is severe pain during menstruation as well as chronic pelvic pain throughout the menstrual cycle or during intercourse. In addition, endometriosis is a leading cause of infertility. The World Endometriosis Research Foundation estimates that endometriosis affects one in ten women during their reproductive years, representing approximately 176 million women worldwide. The World Endometriosis Research Foundation`s EndoCost study estimated the aggregate annual cost of endometriosis to be approximately $80 billion in the United States and approximately $60 billion in Germany, the U.K., France and Italy in 2012 based on current exchange rates.

Endometriosis is a disease in which the endometrium (tissue lining the inside of the uterus) is found outside the uterus, where it induces a chronic inflammatory reaction that may result in scar tissue. It is primarily found on the pelvic endometrium, on the ovaries, in the rectovaginal septum, on the bladder and bowel. The most common symptom of endometriosis is pelvic pain, which often correlates to the menstrual cycle. Patients may also experience painful ovulation, pain during or after sexual intercourse, dyschezia (difficult or painful defecation), heavy bleeding, chronic pelvic pain, fatigue and infertility. Endometriosis pain can be so severe and debilitating that it affects day-to-day activities and has a negative impact on general, physical, mental and social well-being. Endometriosis treatments aim first to alleviate pain, then to remove or decrease the size and number of endometrial lesions, and possibly improve fertility. Oral contraceptives, progestins and NSAIDs are generally first-line treatments for women experiencing pain. Following the failure of first-line therapies, current treatment options are limited to intra-muscular or subcutaneous GnRH agonist injections, GnRH agonists nasal spray pumps or surgery (including hysterectomy) for the most symptomatic cases.

About LINZAGOLIX (OBE2109)

Linzagolix is a novel, orally administered GnRH receptor antagonist with a potentially best-in-class profile in late stage clinical development for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids. Linzagolix acts by binding to and blocking the GnRH receptor in the pituitary gland, ultimately reducing estrogen production by the ovaries. Given reported results from this class of drugs and sophisticated pharmacological modelling, linzagolix is being developed to potentially provide two regimens of administration, one targeting partial suppression of estradiol that may not necessitate add-back therapy (ABT) in the majority of patients,  and one targeting full or near full estradiol suppression that would require the administration of ABT, with the goal of providing appropriate treatment to the broadest possible proportion of the endometriosis and uterine fibroid patient populations.  ObsEva licensed OBE2109 from Kissei in 2015 and retains worldwide rights, excluding Asia.

To date, more than 1500 subjects have been exposed to linzagolix.

About Kissei

Kissei is a Japanese pharmaceutical company with approximately 70 years of history, specialized in the field of urology, kidney-dialysis and unmet medical needs. Silodosin is a Kissei product for the treatment of the signs and symptoms of benign prostatic hyperplasia which is sold worldwide through its licensees. KLH-2109/OBE2109/linzagolix is a new chemical entity discovered by Kissei R&D.

About ObsEva

ObsEva is a clinical-stage biopharmaceutical company focused on the clinical development and commercialization of novel therapeutics for serious conditions that compromise a woman`s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor and improving IVF outcomes. ObsEva is listed on the NASDAQ Global Select Market and is trading under the ticker symbol "OBSV". For more information, please visit www.ObsEva.com.

Cautionary Note Regarding Forward Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as "believe", "expect", "may", "plan," "potential," "will," and similar expressions, and are based on ObsEva`s current beliefs and expectations. These forward-looking statements include expectations regarding the clinical development of ObsEva`s product candidates and the timing of enrollment in and data from clinical trials as well as the feedback from and clinical requirements of relevant regulatory authorities. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, including that past results may differ from future results in the EDELWEISS clinical trial or any future clinical trials, ObsEva`s reliance on third parties over which it may not always have full control, feedback from relevant regulatory authorities, and other risks and uncertainties that are described in the Risk Factors section of ObsEva`s Annual Report on Form 20-F for the year ended December 31, 2017 and other filings ObsEva makes with the SEC. These documents are available on the Investors page of ObsEva`s website at http://www.obseva.com. Any forward-looking statements speak only as of the date of this press release and are based on information available to ObsEva as of the date of this release, and ObsEva assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.

###

Media Contact:

Jeanene Timberlake

RooneyPartners LLC

jtimberlake@rooneyco.com

+1-646-770-8858

CEO Office Contact:

Shauna Dillon

Shauna.dillon@obseva.ch

+41 22 552 1550

Investor Contact:

Mario Corso

Senior Director, Investor Relations

mario.corso@obseva.com

+1-857-972-9347 Office

+1-781-366-5726 Mobile


[1] Recommended by the International Association for the Study of Pain, Farrar et al. 2001 and Vincent et al. 2010.

Press Release

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: ObsEva SA via GlobeNewswire

HUG#2199686

Source : https://finance.yahoo.com/news/obseva-sa-achieves-primary-secondary-110100574.html

2631
ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Source:Yahoo Finance

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Source:GlobeNewswire

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Source:The Valdosta Daily Times

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Source:Yahoo Finance

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis

Source:GlobeNewswire

ObsEva SA Achieves Primary And Secondary Endpoints For EDELWEISS Phase 2b Clinical Trial Of Linzagolix (OBE2109) In Women With Endometriosis